A step behind its major exosome challenger, Evox scores $95M round for final leg of race to the clinic

A step behind its major exosome challenger, Evox scores $95M round for final leg of race to the clinic

Source: 
Endpoints
snippet: 

After years of academic and early-stage biotech development, exosomes finally entered the clinic last year, when Codiak launched their Phase I/II trial in advanced solid tumors. Now Evox, their chief rival in the space, is plotting their own path to humans, even if they still have a ways to go.